Sugi Predict

Sugi Predict / Compounds / SCHEMBL4477423

SCHEMBL4477423

SCHEMBL4477423

Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 16/20 0.78
▸ FLT3 P36888 13/20 0.78
▸ LCK P06239 10/20 0.78
▸ FGFR1 P11362 10/20 0.78
▸ FLT1 P17948 10/20 0.78
▸ AURKA O14965 9/20 0.78
▸ ROCK2 O75116 9/20 0.78
▸ MAP4K4 O95819 9/20 0.78
▸ LYN P07948 9/20 0.78
▸ BLK P51451 9/20 0.78
▸ NEK2 P51955 9/20 0.78
▸ STK3 Q13188 9/20 0.78
▸ ROCK1 Q13464 9/20 0.78
▸ TAOK1 Q7L7X3 9/20 0.78
▸ AXL P30530 9/20 0.78
▸ HIPK4 Q8NE63 9/20 0.78
▸ RPS6KB1 P23443 9/20 0.78
▸ CSF1R P07333 9/20 0.78
▸ MAP4K2 Q12851 8/20 0.78
▸ SLK Q9H2G2 8/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477490 0.89 KDR (0.81) KDRFLT3LCKFGFR1FLT1
SCHEMBL4474877 0.89 KDR (0.80) KDRFLT3LCKFGFR1FLT1
SCHEMBL4486611 0.88 KDR (1.00) KDRFLT3LCKFGFR1FLT1
SCHEMBL232042 0.88 KDR (1.00) KDRFLT3LCKFGFR1FLT1
SCHEMBL4478814 0.88 KDR (0.78) KDRFLT3LCKFGFR1FLT1
SCHEMBL4477648 0.88 KDR (1.00) KDRFLT3LCKFGFR1FLT1
SCHEMBL4477343 0.87 KIT (0.75) KDRFLT3LCKFGFR1FLT1
SCHEMBL4472448 0.87 KDR (0.80) KDRFLT3LCKFGFR1FLT1
SCHEMBL4721626 0.86 STK3 (0.78) KDRFLT3LCKFGFR1FLT1
SCHEMBL4473073 0.85 KDR (0.77) KDRFLT3LCKFGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885LCK 3/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885FLT3 16/4885LCK 2/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885LCK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.